Investigate the Responsiveness of the Erectile Quality Scale to Vardenafil Flexible Dose vs Placebo in Males With Erectile Dysfunction (ED)
A Randomized, Double Blind, Placebo-controlled, Parallel Group, Multi-center Study to Investigate the Responsiveness of the Erectile Quality Scale (EQS) to Vardenafil HCl Flexible Dose Versus Placebo in Males With Erectile Dysfunction.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85023
-
-
California
-
Beverly Hills, California, United States, 90212
-
Laguna Hills, California, United States, 92653
-
Newport Beach, California, United States, 92660
-
-
Colorado
-
Aurora, Colorado, United States, 80012
-
-
Connecticut
-
Trumbull, Connecticut, United States, 06611
-
-
Florida
-
Aventura, Florida, United States, 33180
-
-
New Jersey
-
Lawrenceville, New Jersey, United States, 08648
-
-
New York
-
Poughkeepsie, New York, United States, 12601
-
-
North Carolina
-
Statesville, North Carolina, United States, 28677
-
Wilmington, North Carolina, United States, 28401
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Arm 2
|
5m, 10 mg and 20 mg 1 h prior to sexual intercourse
|
|
Placebo Comparator: Arm 1
|
Matching placebo
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Erection Quality Scale
Time Frame: Week 8
|
Week 8
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Erection Quality Scale
Time Frame: Week 4 and 8
|
Week 4 and 8
|
|
International Index of Erectile Function- Erectile Function domain score
Time Frame: Week 4 and 8
|
Week 4 and 8
|
|
Per-subject success rates based on Sexual Encounter Profile, Question 2
Time Frame: Week 4, 8 Week 8
|
Week 4, 8 Week 8
|
|
Safety and tolerability
Time Frame: Week 8
|
Week 8
|
|
Patient Diary Questions
Time Frame: Weeks 4, 8 Week 8
|
Weeks 4, 8 Week 8
|
|
Global Assessment Question (GAQ)
Time Frame: Weeks 4, 8 of treatment and Week 8
|
Weeks 4, 8 of treatment and Week 8
|
|
Percentage of subjects achieving back to normal rates of erectile functioning (IIEF-EF > 25)
Time Frame: Week 8-LOCF
|
Week 8-LOCF
|
|
Penetration (SEP2) and Maintenance (SEP3) reliability
Time Frame: Week 8-LOCF
|
Week 8-LOCF
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 11561
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.